IL257314B - Selected amide of gamma-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse - Google Patents
Selected amide of gamma-hydroxybutyric acid and uses thereof in the treatment of alcohol misuseInfo
- Publication number
- IL257314B IL257314B IL257314A IL25731418A IL257314B IL 257314 B IL257314 B IL 257314B IL 257314 A IL257314 A IL 257314A IL 25731418 A IL25731418 A IL 25731418A IL 257314 B IL257314 B IL 257314B
- Authority
- IL
- Israel
- Prior art keywords
- gamma
- treatment
- hydroxybutyric acid
- alcohol misuse
- selected amide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITUB2015A002860A ITUB20152860A1 (en) | 2015-08-04 | 2015-08-04 | Selected amide of? -Hydroxybutyric acid and its uses in the treatment of alcohol abuse |
| PCT/EP2016/068517 WO2017021438A1 (en) | 2015-08-04 | 2016-08-03 | SELECTED AMIDE OF γ -HYDROXYBUTYRIC ACID AND USES THEREOF IN THE TREATMENT OF ALCOHOL MISUSE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL257314A IL257314A (en) | 2018-03-29 |
| IL257314B true IL257314B (en) | 2020-04-30 |
Family
ID=54542363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL257314A IL257314B (en) | 2015-08-04 | 2018-02-01 | Selected amide of gamma-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10336687B2 (en) |
| EP (1) | EP3331853B1 (en) |
| JP (1) | JP6832336B2 (en) |
| KR (1) | KR20180066033A (en) |
| CN (1) | CN108026029B (en) |
| AU (1) | AU2016302869B2 (en) |
| CA (1) | CA2994599C (en) |
| CL (1) | CL2018000282A1 (en) |
| CO (1) | CO2018002428A2 (en) |
| DK (1) | DK3331853T3 (en) |
| EA (1) | EA033769B9 (en) |
| ES (1) | ES2776628T3 (en) |
| GE (1) | GEP20207107B (en) |
| IL (1) | IL257314B (en) |
| IT (1) | ITUB20152860A1 (en) |
| MX (1) | MX2018001239A (en) |
| MY (1) | MY185942A (en) |
| PH (1) | PH12018550008A1 (en) |
| PL (1) | PL3331853T3 (en) |
| PT (1) | PT3331853T (en) |
| UA (1) | UA121994C2 (en) |
| WO (1) | WO2017021438A1 (en) |
| ZA (1) | ZA201801402B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019025932A1 (en) * | 2017-07-31 | 2019-02-07 | Novartis Ag | Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use |
| KR20200035035A (en) | 2017-07-31 | 2020-04-01 | 노파르티스 아게 | Use of mabogluant for reducing cocaine use or preventing recurrence of cocaine |
| CN113185403A (en) * | 2021-07-02 | 2021-07-30 | 山东国邦药业有限公司 | Method for preparing cyclopropylamine intermediate methyl cyclopropanecarboxylate from methyl ether |
| WO2023126076A1 (en) * | 2022-01-03 | 2023-07-06 | Laboratorio Farmaceutico C.T. S.R.L. | Medical use of an amide of y-hydroxybutyric acid in the treatment of fragile x syndrome |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1283782B1 (en) * | 1996-08-09 | 1998-04-30 | Ct Lab Farm Srl | USE OF AMIDES OF GAMMA-HYDROXYBUTYRIC ACID IN THE TREATMENT OF TOXIC ADDICTION, AND IN PARTICULAR IN ALCOHOLISM |
-
2015
- 2015-08-04 IT ITUB2015A002860A patent/ITUB20152860A1/en unknown
-
2016
- 2016-08-03 PT PT167913136T patent/PT3331853T/en unknown
- 2016-08-03 AU AU2016302869A patent/AU2016302869B2/en active Active
- 2016-08-03 EP EP16791313.6A patent/EP3331853B1/en active Active
- 2016-08-03 MX MX2018001239A patent/MX2018001239A/en active IP Right Grant
- 2016-08-03 PL PL16791313T patent/PL3331853T3/en unknown
- 2016-08-03 US US15/750,047 patent/US10336687B2/en active Active
- 2016-08-03 UA UAA201801726A patent/UA121994C2/en unknown
- 2016-08-03 CN CN201680045364.9A patent/CN108026029B/en active Active
- 2016-08-03 DK DK16791313.6T patent/DK3331853T3/en active
- 2016-08-03 WO PCT/EP2016/068517 patent/WO2017021438A1/en active Application Filing
- 2016-08-03 EA EA201890419A patent/EA033769B9/en not_active IP Right Cessation
- 2016-08-03 JP JP2018502356A patent/JP6832336B2/en active Active
- 2016-08-03 MY MYPI2018700405A patent/MY185942A/en unknown
- 2016-08-03 ES ES16791313T patent/ES2776628T3/en active Active
- 2016-08-03 GE GEAP201614717A patent/GEP20207107B/en unknown
- 2016-08-03 KR KR1020187006231A patent/KR20180066033A/en active IP Right Grant
- 2016-08-03 CA CA2994599A patent/CA2994599C/en active Active
-
2018
- 2018-01-31 CL CL2018000282A patent/CL2018000282A1/en unknown
- 2018-02-01 IL IL257314A patent/IL257314B/en active IP Right Grant
- 2018-02-02 PH PH12018550008A patent/PH12018550008A1/en unknown
- 2018-02-28 ZA ZA2018/01402A patent/ZA201801402B/en unknown
- 2018-03-02 CO CONC2018/0002428A patent/CO2018002428A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN108026029B (en) | 2020-12-04 |
| PL3331853T3 (en) | 2020-06-15 |
| ITUB20152860A1 (en) | 2017-02-04 |
| EA033769B1 (en) | 2019-11-22 |
| ES2776628T3 (en) | 2020-07-31 |
| EA033769B9 (en) | 2020-04-10 |
| WO2017021438A1 (en) | 2017-02-09 |
| DK3331853T3 (en) | 2020-03-16 |
| CA2994599A1 (en) | 2017-02-09 |
| US20180230086A1 (en) | 2018-08-16 |
| PT3331853T (en) | 2020-02-25 |
| MY185942A (en) | 2021-06-14 |
| CA2994599C (en) | 2023-08-29 |
| AU2016302869A1 (en) | 2018-03-15 |
| UA121994C2 (en) | 2020-08-25 |
| MX2018001239A (en) | 2018-07-06 |
| US10336687B2 (en) | 2019-07-02 |
| CL2018000282A1 (en) | 2018-07-13 |
| EP3331853A1 (en) | 2018-06-13 |
| CO2018002428A2 (en) | 2018-07-10 |
| KR20180066033A (en) | 2018-06-18 |
| JP6832336B2 (en) | 2021-02-24 |
| JP2018523644A (en) | 2018-08-23 |
| EA201890419A1 (en) | 2018-07-31 |
| PH12018550008A1 (en) | 2018-07-09 |
| GEP20207107B (en) | 2020-05-11 |
| IL257314A (en) | 2018-03-29 |
| GEAP202014717A (en) | 2020-01-27 |
| EP3331853B1 (en) | 2019-12-11 |
| ZA201801402B (en) | 2019-01-30 |
| AU2016302869B2 (en) | 2020-10-22 |
| CN108026029A (en) | 2018-05-11 |
| BR112018002245A2 (en) | 2018-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2400028I1 (en) | Pd-1-binding molecules and methods of use thereof | |
| HK1252827A1 (en) | Lag-3-binding molecules and methods of use thereof | |
| LT3334422T (en) | Use of cannabidiolic acid in the treatment of epilepsy | |
| GB201411496D0 (en) | Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy | |
| SG11201605383RA (en) | Aflatoxin nanobody immunoabsorbent and immunoaffinity column and preparation method and use thereof | |
| IL282482A (en) | Protoxin-ii variants and methods of use | |
| ZA201704726B (en) | Peptides and their use in the treatment of skin | |
| IL282508A (en) | Protoxin-ii variants and methods of use | |
| IL257314B (en) | Selected amide of gamma-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse | |
| PT3177599T (en) | Fumarate analogs and uses thereof in the treatment of an autoimmune disease or an inflammatory disease | |
| PL3445354T3 (en) | Azelaic acid esters in the treatment of insulin resistance | |
| ZA201802201B (en) | Novel formulation and treatment methods | |
| GB201508518D0 (en) | Hair treatment compositions and methods | |
| AP2017009817A0 (en) | Capsaicinoids and uses thereof as medicaments | |
| GB201409262D0 (en) | Hair treatment compositions and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |